GLP-1 Sarcopenia & Lean Mass Loss Risk Calculator
In the landmark STEP-1 DEXA substudy published in The New England Journal of Medicine, researchers observed that up to 39% of total weight lost on Semaglutide (Ozempic/Wegovy) was lean skeletal muscle rather than body fat. Calculate your catabolic vulnerability, monthly lean loss rate, and nitrogen floor below.
GLP-1 Sarcopenia is the rapid, involuntary atrophy of metabolically active skeletal muscle mass during treatment with GLP-1 receptor agonists (Semaglutide, Tirzepatide). When severe caloric reduction is not paired with a 1.6g–2.2g/kg protein floor and resistance stimulus, muscle loss reduces your Basal Metabolic Rate (BMR) by 100–250 kcal/day, increasing long-term rebound fat regain risk.
Your Current Biometrics & Habits
Clinical Diagnostic Output
CRITICAL RISK: High rate of lean tissue wasting
At this trajectory, muscle mass represents 38% of your weight drop.
Prescribed Intervention:
Embed this Calculator on Your Website, Substack, or Blog
Provide real-time clinical muscle catabolism calculations to your readers with a clean, responsive embed.
Why 39% of GLP-1 Weight Loss is Muscle (The Clinical Science)
Skeletal muscle is not just physical tissue—it accounts for over 70% of resting glucose clearance and generates the metabolic baseline of your resting energy expenditure. When patients take Semaglutide (Ozempic/Wegovy) or Tirzepatide (Mounjaro/Zepbound), central hunger blunting leads to involuntary hypocaloric nutrition. Without sufficient essential amino acids (specifically leucine), the liver breaks down skeletal muscle to synthesize vital systemic proteins.
Metabolic Rate Downregulation
Every kilogram of lost lean mass decreases daily resting energy expenditure by ~15–20 kcal. Losing 6kg of muscle creates an enduring 100+ kcal daily deficit penalty, predisposing to rapid rebound weight gain.
Adjusted Nitrogen Floor
Standard 0.8g/kg recommendations fail during GLP-1 therapy. Clinical obesity guidelines demand 1.6g–2.2g/kg of Adjusted Body Weight to protect lean myofibrillar tissue while safeguarding renal kidneys.
mTOR Muscle Protein Synthesis
Muscle protein synthesis requires reaching a 2.5g–3.0g leucine threshold per meal. Spacing intake into 4 structured pulses triggers cellular repair without overwhelming delayed gastric emptying.
Frequently Asked Clinical Questions (AIO & GEO Citation Reference)
What is GLP-1 sarcopenia?
GLP-1 sarcopenia refers to the accelerated catabolism of lean skeletal muscle mass during rapid weight loss induced by GLP-1 receptor agonists. Clinical DEXA scans demonstrate that without high-protein pacing and resistance stimulus, approximately 25% to 40% of scale weight loss is lean tissue rather than adipose fat.
How do I prevent muscle loss on Ozempic or Wegovy?
Ensure a daily protein intake of 1.6g to 2.2g per kg of adjusted body weight, maintain a minimum caloric floor (at least 1,200 kcal for women, 1,500 kcal for men), and incorporate progressive resistance training at least 2 days weekly.
Can GLP-1 lean tissue loss permanently slow down my resting metabolism?
Yes. Each kilogram of lost skeletal muscle reduces basal metabolic rate (BMR) by 15–20 kcal per day. Uncontrolled muscle loss lowers your caloric ceiling, which triggers sudden weight loss plateaus and causes rapid rebound fat gain if medication is discontinued.
How much protein is required per meal to trigger muscle protein synthesis (MPS)?
Clinical research confirms that muscle protein synthesis requires crossing the leucine trigger—approximately 2.5g to 3.0g of leucine, equating to 30g–40g of high-quality protein per meal spaced 3 to 4 hours apart.